TenX Keane Acquisition announces separate trading of ordinary shares and rights effective Dec 8, 2022

CITIUS ONCOLOGY, INC.

Holders of 6,600,000 units from IPO may elect to separate shares and rights starting Dec 8.
Separated ordinary shares will trade under TENK; rights under TENKR; units continue as TENKU.
Separation requires contacting transfer agent American Stock Transfer & Trust Company.
No financial terms, business combination, or change in strategy announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.